Search company, investor...

KeyMed Biosciences

keymedbio.com

Founded Year

2016

Stage

IPO | IPO

Total Raised

$84.3M

Date of IPO

7/8/2021

Market Cap

14.73B

About KeyMed Biosciences

KeyMed Biosciences (02162.HK) is a drug research and development company based in China.

Headquarters Location

Building D2 Chengdu Tianfu International Bio-town

Chengdu, Sichuan,

China

028-88610620

Missing: KeyMed Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: KeyMed Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

KeyMed Biosciences Patents

KeyMed Biosciences has filed 1 patent.

The 3 most popular patent topics include:

  • Human proteins
  • Indoles
  • Integral membrane proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/15/2020

Application

Application Date

4/15/2020

Grant Date

Title

Related Topics

Status

Application

Latest KeyMed Biosciences News

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

Sep 22, 2022

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer Share: CHENGDU, China, Sept. 22, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted CMG901 the Breakthrough Therapy Designation for the treatment of advanced gastric and gastroesophageal junction(GEJ) cancer which have relapsed and/or are intolerant to prior therapies. About CMG901 CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors. In April 2022, the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation[i] and Orphan Drug Designation[ii] as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancer which are resistant/refractory to prior therapies. About CDE's Breakthrough Therapy Designation CDE's Breakthrough Therapy Designation is designed to expedite the clinical development of innovative drugs presenting significant clinical advantages. A breakthrough therapy must provide effective treatment for a seriously debilitating or life-threatening condition that has no effective therapy or demonstrate substantial improvement over available therapies. According to the CDE, BTD provides opportunities for more intensive CDE guidance and discussion with respect to clinical trials and development strategy, and for priority review later. For additional information, please visit website: http://en.keymedbio.com/ Reference [i] FDA granted CMG901 fast track designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies. News release. Keymed Biosciences. April 19, 2022. Accessed September 12, 2022. https://prn.to/3jXET0G [ii] CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the orphan-drug designation by the Food and Drug Administration of the United States. News release. Keymed Biosciences. April 12, 2022. Accessed September 12, 2022. https://prn.to/3vGqR9o

KeyMed Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

KeyMed Biosciences Rank

KeyMed Biosciences Frequently Asked Questions (FAQ)

  • When was KeyMed Biosciences founded?

    KeyMed Biosciences was founded in 2016.

  • Where is KeyMed Biosciences's headquarters?

    KeyMed Biosciences's headquarters is located at Building D2, Chengdu.

  • What is KeyMed Biosciences's latest funding round?

    KeyMed Biosciences's latest funding round is IPO.

  • How much did KeyMed Biosciences raise?

    KeyMed Biosciences raised a total of $84.3M.

  • Who are the investors of KeyMed Biosciences?

    Investors of KeyMed Biosciences include Hankang Equity Investment Management and Legend Star.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.